Most Read Articles
Elaine Soliven, 28 Jun 2019
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Elaine Soliven, 18 Jun 2019
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Audrey Abella, 6 days ago
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.

Akt/mTOR, STAT3, ERK, PD-L1 expression linked to DFSP development, progression

21 Oct 2018

Local recurrence or metastasis of dermatofibrosarcoma protuberans (DFSP) may be predicted by complex factors beyond fibrosarcomatous subtype, according to a recent study.

Moreover, development and/or progression of DFSP appear to be associated with expression of protein kinase B (Akt)/mammalian target of rapamycin (mTOR), signal transducer and activator of transcription 3 (STAT3), extracellular signal regulated kinase (ERK) and programmed death ligand 1 (PD-L1).

Nine recurrent DFSPs had larger tumour size, deeper invasion beyond the subcutis and more diverse histologic subtype compared with 35 noncurrent DFSPs. The fibrosarcomatous subtype showed a high cyclin D1–positive index and frequent mitotic figures.

Two metastatic DFSPs (one each of the fibrosarcomatous and myxoid subtypes) revealed four and 11 instances of local recurrence, respectively. These DFSPs also demonstrated larger tumour size, deeper invasion beyond the subcutis and high expression of cyclin D1.

Expression of Akt/mTOR, STAT3, ERK and PD-L1 was none or low in the primary skin lesions and high in the corresponding metastatic sites. DFSP had more frequent expression of Akt/mTOR and ERK than did dermatofibroma.

In this study, the authors performed clinicopathologic and immunohistochemical analyses for 44 DFSPs having wide local excision and 92 dermatofibromas as controls to determine the features and key factors for adverse outcome in DFSP, as well as the implication of expression of Akt/mTOR, STAT3, ERK, cyclin D1 and PD-L1.

The study was limited by the lack of data on patients prior to hospital evaluation.

“Little is known regarding oncoproteins other than platelet-derived growth factor subunit B in DFSP. Moreover, the risk factors for worse prognosis are controversial,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 28 Jun 2019
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Elaine Soliven, 18 Jun 2019
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Audrey Abella, 14 Jun 2019
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Audrey Abella, 6 days ago
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.